[go: up one dir, main page]

ES2813698T8 - Vectores de AAV que comprenden un gen que codifica el factor VIII - Google Patents

Vectores de AAV que comprenden un gen que codifica el factor VIII

Info

Publication number
ES2813698T8
ES2813698T8 ES14771729T ES14771729T ES2813698T8 ES 2813698 T8 ES2813698 T8 ES 2813698T8 ES 14771729 T ES14771729 T ES 14771729T ES 14771729 T ES14771729 T ES 14771729T ES 2813698 T8 ES2813698 T8 ES 2813698T8
Authority
ES
Spain
Prior art keywords
gene encoding
factor viii
aav vectors
encoding factor
aav
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14771729T
Other languages
English (en)
Other versions
ES2813698T3 (es
Inventor
Peter Cameron Colosi
Amit Nathwani
Jenny Mcintosh
Edward Tuddenham
Andrew Davidoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University College London
St Jude Childrens Research Hospital
Biomarin Pharmaceutical Inc
Original Assignee
University College London
St Jude Childrens Research Hospital
Biomarin Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51585244&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2813698(T8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University College London, St Jude Childrens Research Hospital, Biomarin Pharmaceutical Inc filed Critical University College London
Application granted granted Critical
Publication of ES2813698T3 publication Critical patent/ES2813698T3/es
Publication of ES2813698T8 publication Critical patent/ES2813698T8/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ES14771729T 2013-09-12 2014-09-10 Vectores de AAV que comprenden un gen que codifica el factor VIII Active ES2813698T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361877042P 2013-09-12 2013-09-12
PCT/US2014/054960 WO2015038625A1 (en) 2013-09-12 2014-09-10 Adeno-associated virus factor viii vectors

Publications (2)

Publication Number Publication Date
ES2813698T3 ES2813698T3 (es) 2021-03-24
ES2813698T8 true ES2813698T8 (es) 2022-01-26

Family

ID=51585244

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14771729T Active ES2813698T3 (es) 2013-09-12 2014-09-10 Vectores de AAV que comprenden un gen que codifica el factor VIII

Country Status (34)

Country Link
US (5) US9504762B2 (es)
EP (2) EP3770169A1 (es)
JP (4) JP6735672B2 (es)
KR (2) KR20230006058A (es)
CN (2) CN105636981B (es)
AR (1) AR097657A1 (es)
AU (1) AU2014318890B2 (es)
CA (3) CA3178384A1 (es)
CL (1) CL2016000502A1 (es)
CY (2) CY1124213T1 (es)
DK (1) DK3044231T3 (es)
ES (1) ES2813698T3 (es)
FI (1) FIC20230007I1 (es)
FR (1) FR23C1007I2 (es)
HK (1) HK1226416A1 (es)
HR (1) HRP20201324T1 (es)
HU (2) HUE050484T2 (es)
IL (2) IL244404B (es)
LT (2) LT3044231T (es)
MX (2) MX2016003262A (es)
NL (1) NL301222I2 (es)
NO (1) NO2023003I1 (es)
NZ (1) NZ716549A (es)
PE (1) PE20160769A1 (es)
PH (1) PH12016500328A1 (es)
PL (1) PL3044231T3 (es)
PT (1) PT3044231T (es)
RS (1) RS61039B1 (es)
RU (1) RU2710307C2 (es)
SG (1) SG11201601932UA (es)
SI (1) SI3044231T1 (es)
SM (1) SMT202000458T1 (es)
TW (1) TWI632239B (es)
WO (1) WO2015038625A1 (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201210357D0 (en) 2012-06-12 2012-07-25 Ucl Business Plc Factor VIII sequences
WO2015038625A1 (en) 2013-09-12 2015-03-19 Biomarin Pharmaceutical Inc. Adeno-associated virus factor viii vectors
US10335466B2 (en) 2014-11-05 2019-07-02 Voyager Therapeutics, Inc. AADC polynucleotides for the treatment of parkinson's disease
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
JP6879486B2 (ja) * 2015-03-17 2021-06-02 フリーイェ・ユニヴェルシテイト・ブリュッセルＶｒｉｊｅ Ｕｎｉｖｅｒｓｉｅｉｔ Ｂｒｕｓｓｅｌ Ｆｖｉｉｉおよびｆｉｘ用の最適化された肝臓特異的発現系
TWI707951B (zh) * 2015-04-08 2020-10-21 美商健臻公司 過大腺相關載體之製造
EP3626274B1 (en) * 2015-04-16 2025-01-22 Emory University Recombinant promoters and vectors for protein expression in liver and use thereof
PE20241346A1 (es) 2015-09-24 2024-07-03 Biomarin Pharm Inc Vectores del factor viii del virus adeno-asociado, particulas viricas asociadas y formulaciones que los comprenden
JP6909212B2 (ja) 2015-10-28 2021-07-28 サンガモ セラピューティクス， インコーポレイテッド 肝臓特異的コンストラクト、第ｖｉｉｉ因子発現カセット、およびその使用の方法
PE20231949A1 (es) * 2015-10-30 2023-12-05 Spark Therapeutics Inc VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
SG11201804070XA (en) * 2015-11-13 2018-06-28 Baxalta Inc Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
AU2016354550B2 (en) 2015-11-13 2020-04-16 Takeda Pharmaceutical Company Limited Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
KR102450833B1 (ko) * 2016-04-15 2022-10-05 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 혈우병 a 치료용 유전자 요법
US11427809B2 (en) 2016-05-25 2022-08-30 Lonza Houston, Inc. Methods for isolating adeno-associated virus using a polydialkylammonium salt
JP6994018B2 (ja) 2016-07-26 2022-01-14 バイオマリン ファーマシューティカル インコーポレイテッド 新規アデノ随伴ウイルスキャプシドタンパク質
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CA3071519A1 (en) * 2017-08-01 2019-02-07 Spark Therapeutics, Inc. Factor viii (fviii) gene therapy methods
TW202016314A (zh) 2018-05-09 2020-05-01 美商拜奧馬林製藥公司 治療苯丙酮尿症之方法
BR112020023159A2 (pt) 2018-05-14 2021-02-02 Biomarin Pharmaceutical Inc. método para melhorar os sintomas de um transtorno genético em um indivíduo jovem, uso de um vírus aav terapêutico, composição, método para redução do tempo de sangramento, uso de uma quantidade terapeuticamente eficaz de um vírus aav terapêutico e método para aumentar a expressão proteica
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
AU2019306194A1 (en) 2018-07-16 2021-02-04 Baxalta GmbH Gene therapy of hemophilia A using viral vectors encoding recombinant FVIII variants with increased expression
EP3799569A1 (en) * 2018-07-27 2021-04-07 Zentrum für Forschungsförderung in der Pädiatrie GmbH Improved concepts for the treatment of genetic disorders with high-capacity plal-generated gold nanoparticles
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
TWI851647B (zh) 2019-01-16 2024-08-11 日商武田藥品工業股份有限公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
EP3923992A1 (en) 2019-02-15 2021-12-22 CRISPR Therapeutics AG Gene editing for hemophilia a with improved factor viii expression
KR20210151785A (ko) * 2019-03-13 2021-12-14 제너레이션 바이오 컴퍼니 비바이러스성 dna 벡터 및 fviii 치료제 발현을 위한 이의 용도
JP6831943B1 (ja) 2019-10-24 2021-02-17 三ツ星ベルト株式会社 摩擦伝動ベルトおよびその製造方法
CN114929735A (zh) * 2019-11-01 2022-08-19 自由行疗法有限公司 因子viii构建体
US20230340078A1 (en) * 2019-11-14 2023-10-26 Biomarin Pharmaceutical Inc. Treatment of hereditary angioedema with liver-specific gene therapy vectors
JP2023506171A (ja) 2019-12-12 2023-02-15 武田薬品工業株式会社 発現が上昇した組換えｆｖｉｉｉバリアントをコードするウイルスベクターを使用する、血友病ａの遺伝子療法
WO2021236908A2 (en) 2020-05-20 2021-11-25 Biomarin Pharmaceutical Inc. Use of regulatory proteins for the production of adeno-associated virus
CA3183557A1 (en) 2020-06-24 2021-12-30 Bioverativ Therapeutics Inc. Methods for the removal of free factor viii from preparations of lentiviral vectors modified to express said protein
AU2021372262A1 (en) 2020-11-02 2023-06-01 Biomarin Pharmaceutical Inc. Process for enriching adeno-associated virus
US20240269241A1 (en) 2021-06-14 2024-08-15 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
EP4359547A1 (en) * 2021-06-22 2024-05-01 Pfizer Inc. Production of adeno-associated virus vector in insect cells
MX2024001329A (es) * 2021-07-28 2024-04-18 Biomarin Pharm Inc Sistemas de produccion de virus adenoasociados a gran escala.
IL310997A (en) * 2021-08-23 2024-04-01 Bioverativ Therapeutics Inc Factor VIII gene optimization
WO2023036054A2 (en) * 2021-09-08 2023-03-16 Inspirar Limited Composition and method for treating hemophilia
EP4463475A2 (en) 2022-01-14 2024-11-20 Anjarium Biosciences AG Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof
AR128760A1 (es) * 2022-03-11 2024-06-12 Homology Medicines Inc Vectores de expresión con promotores dobles bidireccionales y sus usos
WO2023205300A2 (en) * 2022-04-20 2023-10-26 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus using codon optimized nucleic acid encoding factor viii
TW202417631A (zh) 2022-09-22 2024-05-01 美商拜奧馬林製藥公司 用ａａｖ基因治療載體治療心肌病
WO2024064863A2 (en) 2022-09-22 2024-03-28 Biomarin Pharmaceutical Inc. Treatment of arrhythmogenic cardiomyopathy with aav gene therapy vectors
CN115948408A (zh) * 2022-09-23 2023-04-11 上海信致医药科技有限公司 改进的人凝血因子viii基因表达盒及其应用
WO2024074143A1 (en) * 2022-10-08 2024-04-11 Lingyi Biotech Co., Ltd. Construct for enhancing gene expression
CN116555266B (zh) * 2023-06-09 2024-11-12 呈诺再生医学科技(北京)有限公司 肝脏特异性表达的重组启动子和载体及其在肝脏相关疾病治疗中的应用
WO2025008774A1 (en) 2023-07-05 2025-01-09 Takeda Pharmaceutical Company Limited Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
CN118064436B (zh) * 2024-04-18 2024-07-26 上海凌医生物科技有限公司 一种增强基因表达的嵌合启动子

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
IE58011B1 (en) 1983-05-27 1993-06-16 Texas A & M Univ Sys Method for producing a recombinant baculovirus expression vector
ZA848495B (en) 1984-01-31 1985-09-25 Idaho Res Found Production of polypeptides in insect cells
PL179877B1 (pl) 1993-07-13 2000-11-30 Rhone Poulenc Rorer Sa Zdefektowany replikacyjnie adenowirus, linia komórkowa do infekowania zdefektowanym adenowirusem oraz srodek farmaceutyczny PL PL PL PL PL PL PL PL PL PL
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
US6521225B1 (en) 1996-09-06 2003-02-18 Chiron Corporation AAV vectors
WO2000011149A1 (en) * 1998-08-24 2000-03-02 Uab Research Foundation Methods of producing high titer recombinant adeno-associated virus
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US6221349B1 (en) 1998-10-20 2001-04-24 Avigen, Inc. Adeno-associated vectors for expression of factor VIII by target cells
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
AU2003212708A1 (en) 2002-03-05 2003-09-16 Stichting Voor De Technische Wetenschappen Baculovirus expression system
EP1804839B1 (en) 2004-09-22 2012-03-14 St. Jude Children's Research Hospital Improved expression of factor ix in gene therapy vectors
CN1286981C (zh) * 2004-11-30 2006-11-29 华中科技大学同济医学院附属同济医院 表达人类cyp2j2反义基因的重组腺相关病毒及其制备方法
EP1739179A1 (en) * 2005-06-30 2007-01-03 Octapharma AG Serum-free stable transfection and production of recombinant human proteins in human cell lines
US7943374B2 (en) 2005-08-21 2011-05-17 Markus Hildinger Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
US7943379B2 (en) 2008-04-30 2011-05-17 Nationwide Children's Hospital, Inc. Production of rAAV in vero cells using particular adenovirus helpers
GB0911870D0 (en) 2009-07-08 2009-08-19 Ucl Business Plc Optimised coding sequence and promoter
ES2595160T3 (es) * 2011-10-18 2016-12-28 Csl Behring Gmbh Uso combinado de un glucosaminoglicano sulfatado y una hialuronidasa para mejorar la biodisponibilidad del Factor VIII
CN103215308B (zh) * 2013-02-01 2015-12-23 中国科学院苏州生物医学工程技术研究所 表达重组人fviii的整合质粒、细胞株及其构建方法和应用
WO2015038625A1 (en) 2013-09-12 2015-03-19 Biomarin Pharmaceutical Inc. Adeno-associated virus factor viii vectors

Also Published As

Publication number Publication date
AR097657A1 (es) 2016-04-06
BR112016005576A2 (pt) 2017-09-12
US12239692B2 (en) 2025-03-04
JP7523211B2 (ja) 2024-07-26
NL301222I1 (es) 2023-03-01
CN105636981A (zh) 2016-06-01
JP2023133597A (ja) 2023-09-22
LTPA2023508I1 (es) 2023-04-11
MX2016003262A (es) 2016-09-29
JP2016534739A (ja) 2016-11-10
FR23C1007I2 (fr) 2024-06-14
HK1226416A1 (zh) 2017-09-29
CN105636981B (zh) 2020-11-06
AU2014318890B2 (en) 2019-03-07
RU2019141647A3 (es) 2020-05-18
BR112016005576A8 (pt) 2022-10-18
FIC20230007I1 (fi) 2023-02-08
CA3178379A1 (en) 2015-03-19
CL2016000502A1 (es) 2016-10-21
PT3044231T (pt) 2020-08-27
EP3770169A1 (en) 2021-01-27
CA2921232C (en) 2023-03-14
NL301222I2 (nl) 2023-10-19
RU2710307C2 (ru) 2019-12-26
JP6735672B2 (ja) 2020-08-05
IL244404B (en) 2021-10-31
NO2023003I1 (no) 2023-01-12
CY2023006I1 (el) 2023-06-09
IL244404A0 (en) 2016-04-21
US10463718B2 (en) 2019-11-05
EP3044231A1 (en) 2016-07-20
EP3044231B1 (en) 2020-08-05
AU2014318890A1 (en) 2016-02-25
SI3044231T1 (sl) 2020-12-31
RU2016113702A (ru) 2017-10-17
JP2021072871A (ja) 2021-05-13
RS61039B1 (sr) 2020-12-31
LT3044231T (lt) 2020-11-10
CN112538501A (zh) 2021-03-23
PE20160769A1 (es) 2016-08-12
WO2015038625A1 (en) 2015-03-19
US20170095538A1 (en) 2017-04-06
SMT202000458T1 (it) 2020-11-10
JP2019193675A (ja) 2019-11-07
CY1124213T1 (el) 2022-03-24
NZ716549A (en) 2022-10-28
US20200101140A1 (en) 2020-04-02
CA3178384A1 (en) 2015-03-19
ES2813698T3 (es) 2021-03-24
KR20160049015A (ko) 2016-05-04
MX2021012014A (es) 2021-10-22
US9504762B2 (en) 2016-11-29
RU2019141647A (ru) 2020-01-27
DK3044231T3 (da) 2020-09-07
TWI632239B (zh) 2018-08-11
IL286859A (en) 2021-10-31
US20220339262A1 (en) 2022-10-27
PH12016500328A1 (en) 2016-05-02
US20180161403A1 (en) 2018-06-14
KR102484396B1 (ko) 2023-01-04
CY2023006I2 (el) 2023-11-15
HUS2300003I1 (hu) 2023-01-28
FR23C1007I1 (fr) 2023-03-24
HRP20201324T1 (hr) 2020-11-27
US11406690B2 (en) 2022-08-09
CA2921232A1 (en) 2015-03-19
PL3044231T3 (pl) 2021-01-11
US20150071883A1 (en) 2015-03-12
TW201546285A (zh) 2015-12-16
HUE050484T2 (hu) 2020-12-28
SG11201601932UA (en) 2016-04-28
KR20230006058A (ko) 2023-01-10

Similar Documents

Publication Publication Date Title
ES2813698T8 (es) Vectores de AAV que comprenden un gen que codifica el factor VIII
LT3411478T (lt) Optimizuoti viii faktoriaus genai
DK3889173T5 (da) Optimeret faktor viii-gen
EP2946422A4 (en) ORGANIC ELECTROLUMINESCENT ELEMENT
EP3020576A4 (en) TIRES
LT3031799T (lt) Aromatinis junginys
DK2973235T3 (da) Matrixstregkoder på dåsekomponenter
BR112015024731A2 (pt) pneu
EP2973958A4 (en) MASSIVE REINFORCED ELASTOMER STATOR
EP2990219A4 (en) TIRES
EP3045325A4 (en) Tire
SG11201508817PA (en) Part-stream distillation
GB2534029B (en) Reservoir history matching
LT3030259T (lt) Peptidai
EP2976864A4 (en) RECOMMENDATIONS OF APPLICATION
BR112015017176A2 (pt) isômero isometepteno
GB201308853D0 (en) Genes encoding xylanase
TH148597B (th) ยางล้อสูบลม
CL2013003338S1 (es) Impresora
UA29030S (uk) Логотип «master chief»
UA28956S (uk) Етикетка «сезам»
FR3015989B1 (fr) Potelet flexible